Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Triapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RRM1 known ✓ | P23921 | 1/20 | 1.00 |
| ▸ | RRM2B known ✓ | Q7LG56 | 1/20 | 1.00 |
| ▸ | RRM2 | P31350 | 4/20 | 1.00 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 1.00 |
| ▸ | NCOA3 | Q9Y6Q9 | 3/20 | 0.68 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.68 |
| ▸ | G6PD | P11413 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | CTH | P32929 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triapine SCHEMBL29362841 | 1.00 | RRM2 (1.00) | RRM2RRM1RRM2BCISD1NCOA3 | |
| Triapine SCHEMBL31238438 | 1.00 | RRM2 (1.00) | RRM2RRM1RRM2BCISD1NCOA3 | |
| Triapine SCHEMBL29365763 | 1.00 | RRM2 (1.00) | RRM2RRM1RRM2BCISD1NCOA3 | |
| Triapine SCHEMBL29371 | 1.00 | RRM2 (1.00) | RRM2RRM1RRM2BCISD1NCOA3 | |
| SCHEMBL13622444 | 0.86 | RRM2 (0.76) | RRM2RRM1RRM2BCISD1NCOA3 | |
| SCHEMBL28769421 | 0.85 | RRM2 (0.74) | RRM2RRM1RRM2BCISD1NCOA3 | |
| SCHEMBL6676547 | 0.84 | RRM2 (0.73) | RRM2RRM1RRM2BCISD1NCOA3 | |
| SCHEMBL6676551 | 0.84 | RRM2 (0.73) | RRM2RRM1RRM2BCISD1NCOA3 | |
| SCHEMBL12955602 | 0.84 | RRM2 (0.73) | RRM2RRM1RRM2BCISD1NCOA3 | |
| SCHEMBL29773649 | 0.81 | NCOA3 (1.00) | RRM2RRM1RRM2BCISD1NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3652 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12111313-B2 | Chelator-coated field effect transistor and devices and methods using same | Autonomous Medical Devices Inc. (US) | 2024-10-08 | — | — | US | claimed |
| US-20210369692-A1 | IRON CHELATORS IN TUMOR THERAPY | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2021-12-02 | — | — | US | claimed |
| US-20210293798-A1 | Chelator-Coated Field Effect Transistor and Devices and Methods Using Same | Autonomous Medical Devices Inc. (US) | 2021-09-23 | — | — | US | claimed |
| EP-3837541-A1 | CHELATOR-COATED FIELD EFFECT TRANSISTOR AND DEVICES AND METHODS USING SAME | Autonomous Medical Devices Incorporated (US) | 2021-06-23 | — | — | EP | claimed |
| WO-2021078937-A1 | TREATMENT OF STAT3 RELATED DISEASES BY IRON CHELATORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2021-04-29 | — | — | WO | claimed |
| WO-2020214718-A1 | RRM2 SIGNATURE GENES AS PROGNOSTIC MARKERS IN PROSTATE CANCER PATIENTS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-10-22 | — | — | WO | claimed |
| EP-3713573-A1 | IRON CHELATORS IN TUMOR THERAPY | Deutsches Krebsforschungszentrum (DE) | 2020-09-30 | — | — | EP | claimed |
| WO-2020037078-A1 | CHELATOR-COATED FIELD EFFECT TRANSISTOR AND DEVICES AND METHODS USING SAME | Sensor-Kinesis Corporation (US) | 2020-02-20 | — | — | WO | claimed |
| WO-2019147839-A1 | METHODS AND COMPOSITIONS FOR PRESERVING NEUROGENESIS | SENSEI BIOTHERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | claimed |
| WO-2019101897-A1 | IRON CHELATORS IN TUMOR THERAPY | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2019-05-31 | — | — | WO | claimed |
| US-20080138440-A1 | Methods of diagnosing and alleviating gadolinium toxicity | CORMEDIX INC. (US) | 2008-06-12 | — | — | US | claimed |
| WO-2008066862-A2 | METHODS OF DIAGNOSING AND ALLEVIATING GADOLINIUM TOXICITY | CORMEDIX INC. (US) | 2008-06-05 | — | — | WO | claimed |
| JP-2008510795-A | — | — | 2008-04-10 | — | — | JP | claimed |
| US-20070243132-A1 | Transdermal delivery of pharmaceutical agents | APOLLO LIFE SCIENCES LIMITED (AU) | 2007-10-18 | — | — | US | claimed |
| WO-2007070983-A1 | TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS | APOLLO LIFE SCIENCES LIMITED (AU) | 2007-06-28 | — | — | WO | claimed |
| EP-1789091-A2 | PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS | Nicholas Piramal India Limited (IN) | 2007-05-30 | — | — | EP | claimed |
| US-20060205674-A2 | PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS | NICHOLAS PIRAMAL INDIA LTD. (IN) | 2006-09-14 | — | — | US | claimed |
| WO-2006027711-A2 | PRODRUGS AND CODRUGS CONTAINING BIO- CLEAVABLE DISULFIDE LINKERS | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2006-03-16 | — | — | WO | claimed |
| US-7001888-B2 | Compositions and methods for treating cancer | THRESHOLD PHARMACEUTICALS, INC. (US) | 2006-02-21 | — | — | US | claimed |
| EP-1053012-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTIONS | ENZON PHARMACEUTICALS INC (US) | 2003-07-23 | — | — | EP | claimed |